Biomarker Testing Falls Short in NSCLC

Two studies show that a large fraction of patients with non–small cell lung cancer isn9t receiving biomarker testing. In one study, more than 20% of patients overall weren9t tested before starting treatment. In the second, the testing rate was about 3% lower for African Americans than whites, and the rate of next-generation sequencing was about 10% lower.